The registration certificate of the Class Ⅲ medical device, Poly-L-lactic Acid Microparticle Filler Injection (the “Product”), has been approved by the National Medical Products Administration of China (NMPA).
Xihong Biopharma showcased its regenerative medicine solutions—combining advanced science, innovative manufacturing, and global partnerships.
The injectable poly-L-lactic acid (PLLA)  filler is classified as a Class III medical device and is currently undergoing registrational clinical trials in China...
The parties have entered into a 10-year exclusive master distribution agreement covering two advanced aesthetic products...

Our Blog

Stay ahead with our product & industry blogs
Leave a message
First Name*
Last Name*
Email*
Message*